Radiopharmaceuticals and Tracers

This channel includes news and new technology innovations for nuclear and molecular imaging agents, radiotracers and radiopharmaceuticals used in PET or SPECT imaging. This includes advances in myocardiac perfusion agents.

First reported clinical results from independent clinical experience by University of Augsburg demonstrated encouraging preliminary data for 177Lu-rhPSMA-10.1
News | Radiopharmaceuticals and Tracers
Blue Earth Therapeutics Announces Publication of Results from Independent Clinical Experience with 177Lu-rhPSMA-10.1 in Treatment of Metastatic Castrate Resistant Prostate Cancer

February 21, 2024 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

Time February 21, 2024
arrow
Agreement demonstrates PanTera’s unique ability to support the radionuclide therapeutics industry in bringing new cancer treatments to patients
News | Radiopharmaceuticals and Tracers
PanTera signs agreement with Bayer for the supply of actinium-225

February 14, 2024 — PanTera, the Belgian joint venture created by IBA and SCK CEN to secure large-scale production of ...

Time February 14, 2024
arrow
Radformation, a global pioneer in radiation oncology software solutions, is pleased to announce its strategic partnership with Icon Group, a worldwide leader in comprehensive cancer care.
News | Quality Assurance (QA)
IBA Acquires Radcal Corporation to Expand Medical Imaging Quality Assurance Offering and Strengthen US Presence

February 12, 2024 — IBA, a world leader in particle accelerator technology and a world-leading provider of dosimetry and ...

Time February 12, 2024
arrow
Research Supports RenovoRx’s Lead Oncology Product Candidate, RenovoGem, and its Novel Therapy Platform, TAMP, for the Treatment of Locally Advanced Pancreatic Cancer
News | Interventional Radiology
RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting

February 6, 2024 — RenovoRx, Inc., a clinical-stage biopharmaceutical company developing novel precision oncology ...

Time February 06, 2024
arrow
syngo Virtual Cockpit Enables remote scanning and support for up to three scanners simultaneously
News | Radiology Business
Bayer appoints Nelson Ambrogio as new Head of Radiology Business at Pharmaceuticals Division

January 23, 2024 — Bayer announced Nelson Ambrogio as the new Head of the Radiology Business at its Pharmaceuticals ...

Time January 23, 2024
arrow
Successful completion of contractual site acceptance tests, with 70 MeV cyclotron now fully operational
News | Radiopharmaceuticals and Tracers
iThemba LABS ready to start production of Strontium-82 and Germanium-68 using IBA Cyclone 70

January 23, 2024 — IBA, a world leader in particle accelerator technology and the world’s leading provider of ...

Time January 23, 2024
arrow
With this new approval, people with a Proclaim DRG neurostimulation system can soon receive full-body MRI scans
News | Magnetic Resonance Imaging (MRI)
Abbott Secures FDA Approval for MRI Labeling Expansion for the Proclaim DRG Neurostimulation System

January 18, 2024 — Abbott announced that the U.S. Food and Drug Administration (FDA) has approved expanded MRI labeling ...

Time January 18, 2024
arrow
Under the new agreement, NorthStar will manufacture and distribute patient doses for ongoing Curadh Ac-225 clinical studies and provide Ac-225 for commercial use upon NorthStar’s submission of a Type II Drug Master File (DMF) to the FDA
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes and Curadh MTR Enter Strategic Collaboration Agreement for Development and Production of Actinium-225 (Ac-225)-based Therapeutic Radiopharmaceuticals for Treatment of Primary and Metastatic Solid Tumors

January 5, 2024 — NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and ...

Time January 05, 2024
arrow
Nucleus RadioPharma, a fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, announced the appointment of Kathy Spencer-Pike as Chief Commercial Officer
News | Radiology Business
Nucleus RadioPharma Appoints Former McKesson, Novo Nordisk Executive Kathy Spencer-Pike as Chief Commercial Officer to Drive Business Growth

December 14, 2023 — Nucleus RadioPharma, a fully integrated development, manufacturing, and supply chain organization ...

Time December 14, 2023
arrow
Rigging of the Cyclone 30XP in Poland completed with a further two sites in Germany and France already operational
News | Radiopharmaceuticals and Tracers
IBA Pioneers Theranostic Advancements, Empowering the Market to Produce Astatine-211

December 12, 2023 — IBA, a world leader in particle accelerator technology and of radiopharmaceutical production ...

Time December 12, 2023
arrow
Licensing agreement between Philochem and Blue Earth Diagnostics, one of the Bracco family of companies, encompasses applications of OncoFAP for diagnostic and medical imaging
News | Radiopharmaceuticals and Tracers
Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors

December 6, 2023 — Philochem AG, a wholly owned subsidiary of Philogen S.p.A., and Blue Earth Diagnostics, a Bracco ...

Time December 06, 2023
arrow
Meilleur Technologies, Inc. announced a research collaboration agreement with the Alzheimer’s Disease Neuroimaging Initiative 4, ADNI4
News | Radiopharmaceuticals and Tracers
Meilleur Technologies Inc. Announces Use of the Next-Generation Amyloid PET Imaging Biomarker, NAV-4694, in the Alzheimer’s Disease Neuroimaging Initiative 4 (ADNI4)

October 20, 2023 — Meilleur Technologies, Inc. announced a research collaboration agreement with the Alzheimer’s Disease ...

Time October 20, 2023
arrow
New company will advance Actinium-225 technologies
News | Radiopharmaceuticals and Tracers
ITM and CNL Announce the Launch of Actineer, a New Joint Venture in the Global Production of Actinium-225

October 18, 2023 —ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Canadian ...

Time October 18, 2023
arrow
Radionetics initiates its first clinical program targeting MC2R
News | Radiation Oncology
Radionetics Oncology Announces Initiation of Phase 1 Radiopharmaceutical Program Against a Novel Target for Adrenocortical Carcinoma

October 17, 2023 — Radionetics Oncology, Inc., a clinical stage radiopharmaceutical company focused on the discovery and ...

Time October 17, 2023
arrow
A global licensing agreement has been signed for the development and commercialization of SOFIE’s two investigational Gallium-68 and Fluorine-18 Fibroblast Activation Protein Inhibitors (FAPI) radiopharmaceutical diagnostics - [68Ga]FAPI-46 and outside-U.S. rights for [18F]FAPI-74
News | Radiopharmaceuticals and Tracers
SOFIE and GE HealthCare Enter Licensing Agreement to Develop FAP PET Radiotracers

October 11, 2023 — GE HealthCare today announced an exclusive global licensing agreement with SOFIE Biosciences (SOFIE) ...

Time October 11, 2023
arrow
POSLUMA (flotufolastat F 18) PET/CT image showing uptake in the prostate gland, consistent with primary prostate cancer.
News | Radiopharmaceuticals and Tracers
Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO

October 5, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time October 05, 2023
arrow
POSLUMA is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis
News | Radiopharmaceuticals and Tracers
Blue Earth Diagnostics Highlights Presentations on POSLUMA (Flotufolastat F 18) in Prostate Cancer at Upcoming ASTRO Annual Meeting

September 27, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time September 27, 2023
arrow
This molecule may significantly expand the patient population eligible for SCINTIX therapy to patients with solid tumor cancers of any stage in a manner that may improve both outcomes and procedural workflow
News | Radiation Therapy
RefleXion Acquires Global Rights to Radiopharmaceutical Molecule from 3B Pharmaceuticals to Treat High Unmet Need Cancers

September 20, 2023 — RefleXion Medical, Inc., a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a ...

Time September 20, 2023
arrow
The iba Cyclone IKON
Feature | PET Imaging
PET Radiotracer Market anticipated to reach $3.2 Billion in Revenues by 2031

According to a new report from Transparency Market Research (TMR), PET radiotracers are expected to rise at a CAGR of 8 ...

Time September 05, 2023
arrow
NorthStar’s high purity non-carrier added (n.c.a.) Ac-225 to be used in Curadh’s molecularly targeted radiation (MTR) programs for treatment of solid tumors
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes and Curadh MTR Announce a Strategic Long Term Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)

August 31, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time August 31, 2023
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now